文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

西维来司他钠在脓毒症患者中的疗效与安全性

[Efficacy and safety of sivelestat sodium in patients with sepsis].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2023-01-01
一句话结论回顾性研究显示,脓毒症患者使用西维来司他钠可改善氧合指数和APACHE II评分、降低PCT和CRP、缩短机械通气时间和ICU住院时间,且未观察到肝肾功能损伤和血小板异常等不良反应。

该研究回顾性分析了2019年1月1日至2022年1月1日郑州大学第一附属医院ICU收治的141例成人脓毒症患者,按是否接受西维来司他钠分为西维来司他钠组(n=70)和对照组(n=71)。治疗7天后,西维来司他钠组氧合指数显著高于对照组,PCT、CRP、ALT和APACHE II评分显著低于对照组;SOFA、WBC、SCr、PLT、TBil、AST无显著差异。西维来司他钠组机械通气时间和ICU住院时间显著短于对照组,但住院时间和ICU死亡率无显著差异。作者认为西维来司他钠在脓毒症患者中安全有效。

要点

  • 治疗7天后氧合指数西维来司他钠组233.5(181.0, 278.0)mmHg vs 对照组202.0(153.0, 243.0)mmHg,P<0.01。
  • 治疗7天后PCT西维来司他钠组0.87(0.41, 1.61)μg/L vs 对照组1.53(0.56, 5.33)μg/L,P<0.05;CRP 64.12(19.61, 150.86)mg/L vs 107.20(50.30, 173.00)mg/L,P<0.05。
  • 治疗7天后APACHE II评分西维来司他钠组14(11, 18)vs 对照组16(13, 21),P<0.05;ALT 25.0(15.0, 43.0)U/L vs 31.0(20.0, 65.0)U/L,P<0.05。
  • 机械通气时间西维来司他钠组147.50(86.83, 220.00)小时 vs 对照组182.00(100.00, 360.00)小时,ICU住院时间12.5(9.0, 18.3)天 vs 16.0(11.0, 23.0)天,均P<0.05。
  • ICU死亡率西维来司他钠组17.1%(12/70)vs 对照组14.1%(10/71),住院时间20.0(11.0, 27.3)天 vs 13.0(11.0, 21.0)天,均P>0.05。

适用人群与场景

  • 2019年1月1日至2022年1月1日郑州大学第一附属医院ICU收治的成人脓毒症患者141例。
  • 按是否接受西维来司他钠分为西维来司他钠组(n=70)和对照组(n=71)。

处置流程与药物剂量

  • 西维来司他钠组接受西维来司他钠治疗,对照组未接受西维来司他钠;原文未报告西维来司他钠的剂量、给药途径、频次和疗程。

研究设计与关键结果

  • 研究类型为回顾性分析,样本量141例,人群为成人脓毒症患者,干预为西维来司他钠 vs 对照(未接受西维来司他钠)。
  • 治疗7天后氧合指数西维来司他钠组233.5(181.0, 278.0)mmHg vs 对照组202.0(153.0, 243.0)mmHg,P<0.01。
  • 治疗7天后PCT西维来司他钠组0.87(0.41, 1.61)μg/L vs 对照组1.53(0.56, 5.33)μg/L,P<0.05;CRP 64.12(19.61, 150.86)mg/L vs 107.20(50.30, 173.00)mg/L,P<0.05;ALT 25.0(15.0, 43.0)U/L vs 31.0(20.0, 65.0)U/L,P<0.05;APACHE II评分14(11, 18)vs 16(13, 21),P<0.05。
  • 治疗7天后SOFA评分西维来司他钠组6.5(5.0, 10.0)vs 对照组7.0(5.0, 10.0),WBC 10.5(8.2, 14.7)×10^9/L vs 10.5(7.2, 15.2)×10^9/L,SCr 76.0(50.0, 124.1)μmol/L vs 84.0(59.0, 129.0)μmol/L,PLT 127.5(59.8, 212.3)×10^9/L vs 121.0(55.0, 211.0)×10^9/L,TBil 16.8(10.0, 32.1)μmol/L vs 16.6(8.4, 26.9)μmol/L,AST 31.5(22.0, 62.3)U/L vs 37.0(24.0, 63.0)U/L,均P>0.05。
  • 机械通气时间西维来司他钠组147.50(86.83, 220.00)小时 vs 对照组182.00(100.00, 360.00)小时,P<0.05;ICU住院时间12.5(9.0, 18.3)天 vs 16.0(11.0, 23.0)天,P<0.05。
  • 住院时间西维来司他钠组20.0(11.0, 27.3)天 vs 对照组13.0(11.0, 21.0)天,P>0.05;ICU死亡率17.1%(12/70)vs 14.1%(10/71),P>0.05。

证据类型、等级与局限

  • 证据类型:回顾性分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为西维来司他钠在脓毒症患者中安全有效,可改善氧合指数和APACHE II评分,降低PCT和CRP水平,缩短机械通气时间和ICU住院时间;未观察到肝肾功能损伤和血小板异常等不良反应。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To investigate the efficacy and safety of sivelestat sodium in patients with sepsis.

METHODS: The clinical data of 141 adult patients with sepsis admitted to the intensive care unit (ICU) of the First Affiliated Hospital of Zhengzhou University from January 1, 2019 to January 1, 2022 were retrospectively analyzed. The patients were divided into the sivelestat sodium group (n = 70) and the control group (n = 71) according to whether they received sivelestat sodium or not. The efficacy indexes included oxygenation index, procalcitonin (PCT), C-reactive protein (CRP), white blood count (WBC), sequential organ failure assessment (SOFA), acute physiology and chronic health evaluation II (APACHE II) before and after 7 days of treatment, as well as ventilator supporting time, the length of ICU stay, the length of hospital stay and ICU mortality. The safety indicators included platelet count (PLT) and liver and kidney function.

RESULTS: There were no significant differences in age, gender, underlying diseases, infection site, basic drugs, etiology, oxygenation index, biochemical indexes, SOFA and APACHE II scores between the two groups. Compared with the control group, the oxygenation index in 7 days was significantly increased [mmHg (1 mmHg ≈ 0.133 kPa): 233.5 (181.0, 278.0) vs. 202.0 (153.0, 243.0), P < 0.01], the levels of PCT, CRP, alanine aminotransferase (ALT) and APACHE II score were significantly decreased in the sivelestat sodium group [PCT (μg/L): 0.87 (0.41, 1.61) vs. 1.53 (0.56, 5.33), CRP (mg/L): 64.12 (19.61, 150.86) vs. 107.20 (50.30, 173.00), ALT (U/L): 25.0 (15.0, 43.0) vs. 31.0 (20.0, 65.0), APACHE II: 14 (11, 18) vs. 16 (13, 21), all P < 0.05]. However, there were no significant differences in SOFA, WBC, serum creatinine (SCr), PLT, total bilirubin (TBil), aspartate aminotransferase (AST) in 7 days between the sivelestat sodium group and the control group [SOFA: 6.5 (5.0, 10.0) vs. 7.0 (5.0, 10.0), WBC (×109/L): 10.5 (8.2, 14.7) vs. 10.5 (7.2, 15.2), SCr (μmol/L): 76.0 (50.0, 124.1) vs. 84.0 (59.0, 129.0), PLT (×109/L): 127.5 (59.8, 212.3) vs. 121.0 (55.0, 211.0), TBil (μmol/L): 16.8 (10.0, 32.1) vs. 16.6 (8.4, 26.9), AST (U/L): 31.5 (22.0, 62.3) vs. 37.0 (24.0, 63.0), all P > 0.05]. The ventilator supporting time and the length of ICU stay in the sivelestat sodium group were significantly shorter than those in control group [ventilator supporting time (hours): 147.50 (86.83, 220.00) vs. 182.00 (100.00, 360.00), the length of ICU stay (days): 12.5 (9.0, 18.3) vs. 16.0 (11.0, 23.0), both P < 0.05]. However, there were no significant differences in the length of hospital stay and ICU mortality between the sivelestat sodium group and the control group [the length of hospital stay (days): 20.0 (11.0, 27.3) vs. 13.0 (11.0, 21.0), ICU mortality: 17.1% (12/70) vs. 14.1% (10/71), both P > 0.05].

CONCLUSIONS: Sivelestat sodium is safe and effective in patients with sepsis. It can improve the oxygenation index and APACHE II score, reduce the levels of PCT and CRP, shorten ventilator supporting time and the length of ICU stay. No adverse reactions such as liver and kidney function injury and platelet abnormality are observed.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Qi X, Ding X, Yuan Y, et al. [Efficacy and safety of sivelestat sodium in patients with sepsis]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2023. PMID: 36880238. doi:10.3760/cma.j.cn121430-20220531-00519

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。